- Health2Sync, Asia's leading chronic disease management platform, has secured over $20 million in a Series C funding round, paving the way for a planned public listing on the Taiwan capital markets.
- This capital will fuel strategic growth as Health2Sync prepares for its IPO: expanding into new markets (Japan, South Korea, Australia), developing new disease management programs (weight loss, hypertension, GLP-1), and deepening AI integration.
- This investment reflects strong investor confidence in Health2Sync's established market leadership, its vision to transform chronic disease management through data-driven solutions, and its strategic path towards a public listing.
TAIPEI, TAIWAN - Media OutReach Newswire - 5 March 2025 - Health2Sync (H2), a leading digital health company specializing in chronic disease management, today announced it has raised over US$20 million in a Series C funding round and earlier extension round. This investment will propel the company's growth initiatives, including expansion into new markets, development of innovative programs, and preparations for a public listing in Taiwan.
Register to read this story and more for free.
Signing up for an account helps us improve your browsing experience.
ContinueOR
See our subscription options.
Already have an account? Log in here